Biogen to Test Spinal Muscular Atrophy Drug Spinraza after Treatment with Zolgensma
Biogen plans to initiate a phase 4 clinical study to study its spinal muscular atrophy treatment Spinraza (nusinersen) in infants and children who were previously treated with Novartis’ blockbuster Zolgensma (onasemnogene abeparvovec).
The trial will examine whether Spinraza’s production of the survival motor neuron protein, which supports sitting, walking and basic life functions, can benefit patients previously treated with Zolgensma. It will enroll up to 60 children up to 3 years old who have potential for additional clinical improvement after Zolgensma.
Biogen plans to begin enrolling patients in the first quarter of next year.